Skip to content

Study · Animal study (in vivo) · mouse · 2019

8 results

GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.

Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP

Molecular cancer therapeutics24 Jul 2019Cited by 12 (Europe PMC)

PMID31341032 (opens in a new tab)DOI10.1158/1535-7163.mct-18-1337 (opens in a new tab)PepBankPUB-31341032
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In SCID mice with VCaP xenografts, tumors with degarelix were 67% of the size of tumors with leuprolide.

    In plain wordsIn mice, tumors with degarelix were 67% of the size of tumors with leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseTumor size versus leuprolide
    Study

    mousen: not reported in source

    SCID mice bearing VCaP xenografts
    Comparator
    Leuprolide
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Measurements

    Relative tumor size
    67%
    degarelix versus leuprolide

    Source sentences

    Summary
    Tumors in degarelix-treated mice were 67% of those in the leuprolide-treatment group but 170% larger than in surgically castrated ones.
    1 context sentence
    Summary · context
    SCID mice bearing VCaP xenograft tumors were divided into 4 groups and treated with surgical castration, degarelix, leuprolide, or buffer alone for 4 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In SCID mice with VCaP xenografts, tumors with degarelix were 170% larger than tumors after surgical castration.

    In plain wordsIn mice, tumors with degarelix were 170% larger than tumors after surgical castration.

    Peptide
    Degarelix
    Outcome
    IncreaseTumor size versus surgical castration
    Study

    mousen: not reported in source

    SCID mice bearing VCaP xenografts
    Comparator
    Surgical castration
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Measurements

    Tumor size increase
    170%
    degarelix versus surgical castration

    Source sentences

    Summary
    Tumors in degarelix-treated mice were 67% of those in the leuprolide-treatment group but 170% larger than in surgically castrated ones.
    1 context sentence
    Summary · context
    SCID mice bearing VCaP xenograft tumors were divided into 4 groups and treated with surgical castration, degarelix, leuprolide, or buffer alone for 4 weeks.
  3. 03AnimalOther designMechanism

    Across serum, tumor samples, or treated cell pellets, degarelix decreased testosterone more than leuprolide, which had no inhibitory effect.

    In plain wordsIn mice and cells, degarelix decreased testosterone more than leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseTestosterone levels versus leuprolide
    Study

    n: not reported in source

    Serum, tumor samples, or treated prostate cancer cell pellets
    Comparator
    Leuprolide
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Measurements of intratumoral steroids in serum, tumor samples, or treated cell pellets by LC/MS confirmed that degarelix better decreased the levels of testosterone and steroidogenesis pathway intermediates, comparable to surgical castration, whereas leuprolide had no inhibitory effect.
  4. 04AnimalOther designMechanism

    Across serum, tumor samples, or treated cell pellets, degarelix decreased steroidogenesis intermediates more than leuprolide, which had no inhibitory effect.

    In plain wordsIn mice and cells, degarelix decreased steroid-production intermediates more than leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseSteroidogenesis intermediates versus leuprolide
    Study

    n: not reported in source

    Serum, tumor samples, or treated prostate cancer cell pellets
    Comparator
    Leuprolide
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Measurements of intratumoral steroids in serum, tumor samples, or treated cell pellets by LC/MS confirmed that degarelix better decreased the levels of testosterone and steroidogenesis pathway intermediates, comparable to surgical castration, whereas leuprolide had no inhibitory effect.
  5. 05AnimalOther designMechanism

    Across serum, tumor samples, or treated cell pellets, testosterone reductions with degarelix were comparable to surgical castration.

    In plain wordsIn mice and cells, testosterone reductions with degarelix were comparable to surgical castration.

    Peptide
    Degarelix
    Outcome
    Direction not reportedTestosterone levels versus surgical castration
    Study

    n: not reported in source

    Serum, tumor samples, or treated prostate cancer cell pellets
    Comparator
    Surgical castration
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Measurements of intratumoral steroids in serum, tumor samples, or treated cell pellets by LC/MS confirmed that degarelix better decreased the levels of testosterone and steroidogenesis pathway intermediates, comparable to surgical castration, whereas leuprolide had no inhibitory effect.
  6. 06AnimalOther designMechanism

    Across serum, tumor samples, or treated cell pellets, steroidogenesis intermediate reductions with degarelix were comparable to surgical castration.

    In plain wordsIn mice and cells, reductions in steroid-production intermediates with degarelix were comparable to surgical castration.

    Peptide
    Degarelix
    Outcome
    Direction not reportedSteroidogenesis intermediates versus surgical castration
    Study

    n: not reported in source

    Serum, tumor samples, or treated prostate cancer cell pellets
    Comparator
    Surgical castration
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Measurements of intratumoral steroids in serum, tumor samples, or treated cell pellets by LC/MS confirmed that degarelix better decreased the levels of testosterone and steroidogenesis pathway intermediates, comparable to surgical castration, whereas leuprolide had no inhibitory effect.
  7. 07LabIn vitro (cells)Efficacy outcome

    In LNCaP, C4-2BMDVR, and CWR22Rv1 prostate cancer cells, degarelix reduced viability versus controls (P ≤ 0.01).

    In plain wordsIn cells from human prostate cancers, degarelix reduced viability compared with controls.

    Peptide
    Degarelix
    Outcome
    DecreaseCell viability
    Study

    humann: not reported in source

    LNCaP, C4-2BMDVR, and CWR22Rv1 prostate cancer cells
    Comparator
    Controls
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In LNCaP, C4-2BMDVR, and CWR22Rv1 cells, degarelix significantly reduced cell viability compared with the controls (P ≤ 0.01).
  8. 08LabIn vitro (cells)Mechanism

    In C4-2B MDVR cells, degarelix alone reduced AR-V7 protein expression compared with control.

    In plain wordsIn cells, degarelix alone reduced AR-V7 protein expression compared with control.

    Peptide
    Degarelix
    Outcome
    DecreaseAR-V7 protein expression
    Study

    humann: not reported in source

    C4-2B MDVR prostate cancer cells
    Comparator
    Control
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In C4-2B MDVR cells, degarelix alone or combined with abiraterone or enzalutamide reduced the AR-V7 protein expression compared with the control group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.